Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of delpacibart braxlosiran in people living with facioscapulohumeral muscular dystrophy. A total of 51 participants were enrolled in the Fortitude biomarker cohort.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences’ Promising Developments in DMD Treatment and Strategic Preparations for Future Success
- Buy Rating for Avidity Biosciences Driven by Strategic Leadership and Patient-Centric Approach
- Avidity Biosciences: Strategic Advancements in DMD Program and Promising Market Potential Justify Buy Rating
- Optimistic Buy Rating for Avidity Biosciences Driven by Promising DMD Treatment and Strategic Expansion Plans
- Promising Trial Results and Strong Growth Potential Lead to Buy Rating for Avidity Biosciences